Mandate

Vinge has advised Sveafastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Sveafastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 13 June 2025 and the trading on Nasdaq Stockholm commenced on 18 June 2025.

Sveafastigheter is a real estate company that owns, actively manages and develops residential properties throughout Sweden with a focus on rental apartments in selected growth regions. The property portfolio consists of standing assets, ongoing construction and project development with a total property value of approximately SEK 28.2 billion.

Vinge’s team has primarily consisted of Rikard Lindahl, Benjamin Vafaeian, Filip Magnusson and  Carl Lexenberg (Capital Markets and Public M&A), Victor Ericsson, Emelie Svanberg, Erik Kochbati and Marcus Svärd (Corporate Tax), Emil Lindwall and Agnes Pigg (Employment), Felix Möller and William Carlberg Johansson (Financing), Ian Jonson (IPR), Kristoffer Larson (Real Estate) and Diana Kanold (VDR).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025